[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627437":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":49,"collaborators":24,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":24,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":24,"enrollmentInfo":60,"targetDuration":24,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":24,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","The cohort includes participants that will be evaluated for the cardiac uptake of 89Zr coramitug.",[13],"Drug: Coramitug",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","The cohort includes participants to evaluate the sink effect (if observed in cohort 1) and also evaluate competitive binding between 89Zr-coramitug and different dose levels of coramitug.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Coramitug","Coramitug will be administered intravenously",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Clinical Transparency dept. 2834","STUDY_DIRECTOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[36],{"facility":37,"status":38,"city":39,"state":24,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":24},"ICON - location Groningen","RECRUITING","Groningen","9728 NZ","Netherlands","NL",{"type":44,"coordinates":45},"Point",[46,47],6.56667,53.21917,{"lat":47,"lon":46},{"type":50,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100627437","phase-1-a-research-study-to-look-at-the-distribution-and-effects-of-coramitug-on-amyloid-deposits-in-heart-tissue-using-petct-imaging-in-people-with-attr-amyloidosis-100627437",false,"NCT07448623","A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET\u002FCT Imaging in People With ATTR Amyloidosis.","An Open-label Study to Evaluate the Biodistribution of 89Zr-coramitug and Investigate the Effects of Coramitug on Depleting TTR Amyloid Deposits in Myocardial Tissues Using PET\u002FCT Imaging in Participants With ATTR-CM","Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n* Male or female.\n* Age greater than or equal to (≥) 60 years or above at the time of signing the informed consent.\n* For participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM):\n* Have an established diagnosis of ATTR-CM, with either wild-type Transthyretin (TTR) or variant TTR genotype (ATTRwt) or (ATTRv), with cardiac amyloid infiltration, increased left ventricular (LV) wall thickness, \\& heart failure (HF):\n\n  a) Cardiac amyloid infiltration demonstrated by: i. Cardiac biopsy positive for TTR amyloid, OR ii. Grade 2 or Grade 3 cardiac uptake at pyrophosphate\u002F3,3-diphosphono-1,2-propanodicarboxylic acid\u002Fhydroxymethylene diphosphonate (PYP\u002FDPD\u002FHMDP) scintigraphy with Single-Photon Emission Computed Tomography (SPECT\u002FCT) combined with an extracardiac biopsy positive for TTR amyloid, OR iii. Grade 2 or Grade 3 cardiac uptake at PYP\u002FDPD\u002FHMDP scintigraphy with SPECT\u002FCT combined with normal serum free light chain ratio \\& negative serum \\& urine immunofixation (Serum Immunofixation \\[SPIE\\] and Urine Immunofixation \\[UPIE\\]) Note: Bone tracer scintigraphy using 99m technetium (Tc)-labelled pyrophosphate (99mTc-PYP)\u002F99mTc-labelled 3,3-diphosphono-1,2- propanodicarboxylic acid (99mTc-DPD)\u002F99mTc-labeled hydroxymethylene diphosphonate (99m-Tc-HMDP) b. Increased LV wall thickness, as assessed by echocardiography showing LV posterior and septal wall thickness greater than or equal to (≥)13 millimeter (mm) for women and ≥ 14 mm for men (Note: Pre-existing echocardiogram up to 2 years old can be used).\n\n  c. Chronic HF with: i. At least 1 documented hospitalisation for HF occurring greater than (\\>) 3 months but less than (\\\u003C) 2 years, OR ii. History of HF manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath, signs of pulmonary con-gestion on x-ray or auscultation, or peripheral oedema) requiring ongoing treatment with a loop diuretic.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous participation in this study. Participation is defined as signed informed consent.\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential.\n* Current participation (i.e., signed informed consent) in any other interventional clinical study.\n* Participation in research studies involving exposure to radiation within a year preceding the screening period in this study.","ALL","60 Years",{"count":61,"type":62},14,"ESTIMATED","INTERVENTIONAL",[65],"PHASE1","The study is conducted in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a heart disease that occurs in people with the disease ATTR amyloidosis. The purpose of this study is to see how radioactively labelled coramitug is taken up by the heart after administration through an infusion (Cohort 1), and to understand the extent to which coramitug can be displaced by radioactively labelled coramitug (Cohort 2). In this study it will also be investigated how safe coramitug is and how well it is tolerated when it is used by participants with ATTR-CM. Coramitug is potentially a new medicine for participants with ATTR-CM. Coramitug is a monoclonal antibody that potentially binds to the accumulations of the transthyretin protein and promotes its removal from the heart. It may also prevent the formation of clumps and may help with clearing existing clumps of the abnormal protein. The study will take a maximum of 85 days (for Cohort 1) or 106 days (for Cohort 2) when participating in Period A from the screening until the follow-up visit.",[68],"Transthyretin Amyloid Cardiomyopathy","2026-04-07",{"date":71,"type":72},"2026-04-13","ACTUAL",{"date":74,"type":72},"2026-03-02",{"date":76,"type":62},"2028-07-25",{"name":5,"class":6},1]